Results 141 to 150 of about 130,554 (162)

Low-density Lipoprotein Receptor Activities, Lipids, Apolipoprotein, and Clinical Course of Patients with Steroid-resistant Nephrotic Syndrome Treated with Low-density Lipoprotein Apheresis: A Case Series. [PDF]

Intern Med
Shima H, Higashiguchi Y, Doi T, Harada M, Okamoto T, Inoue T, Tashiro M, Okada K, Minakuchi J.   +8 more
europepmc   +1 more source

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre. [PDF]

Cardiol J, 2019
Mickiewicz A, Borowiec-Wolna J, Bachorski W, Gilis-Malinowska N, Gałąska R, Raczak G, Chmara M, Wasąg B, Jaguszewski MJ, Fijałkowski M, Gruchała M.   +10 more
europepmc   +1 more source

First data from the German Lipoprotein Apheresis Registry (GLAR)

Atherosclerosis Supplements, 2015
Objective: In recent years the Federal Joint Committee (G-BA), a paramount decision-making body of the German health care system challenged the approval of diagnostic and therapeutic procedures for regular reimbursement, including lipoprotein apheresis ...
Volker Schettler, Franz Heigl
exaly   +2 more sources

From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. [PDF]

European Journal of Preventive Cardiology, 2018
In this observational study, we compared the effect of lipoprotein apheresis and evolocumab or alirocumab on levels of lipoprotein cholesterol, triglycerides and inflammatory markers (C reactive protein and interleukin 6) in cardiovascular patients ( n =
Nicola Ferri, Massimiliano Ruscica, Maria Giovanna Lupo   +2 more
exaly   +2 more sources

Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989–2017

Atherosclerosis, 2019
BACKGROUND AND AIMS In 2008, the National Institute of Health and Care Excellence in the UK recommended that patients undergoing lipoprotein apheresis (LA) should be included in an anonymised registry.
Alison Pottle, Gilbert Thompson, Mahmoud Barbir   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

Circulation Research, 2013
Hagai Tavori, Sergio Fazio, MacRae F. Linton   +2 more
exaly  

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization

Arteriosclerosis, Thrombosis, and Vascular Biology, 2016
Børge G. Nordestgaard, Florian Kronenberg, Reinhard Klingel   +2 more
exaly  

Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial

European Heart Journal, 2017
Dudley Pennell, Li-Yueh Hsu, Tina Z Khan
exaly